Imatinib is a promising candidate for the treatment of fibrotic diseases. This retrospective study evaluated the use of imatinib for the treatment of refractory sclerotic chronic graft-versus-host disease in 14 patients with different hematologic malignancies. Imatinib was started at a median of 44 months after transplantation (range, 16-119 months after transplantation) and was administered fo...

background: imatinib is known as the drug of choice for treatment of chronic myeloid leukemia (cml). for adults the recommended daily dosage of 400 mg requires simultaneous intake of up to four capsules or tablets each 100 mg. a new 400 mg film coated tablet developed due to the need to swallow multiple capsules or tablets per dose and that was a negative impact on treatment adherence. subjects...

STI571 (imatinib) is increasingly being used in the treatment of different phases of chronic myeloid leukemia and metastatic gastrointestinal stromal tumors.1,2 Philadelphia-positive acute lymphoblastic leukemia (Ph ALL) has a poor prognosis with the current treatment options.3 Allogenic stem cell transplantation is the only curative management option available to date, the long-term survival b...

BACKGROUND Imatinib mesylate is used in combination with hydroxyurea (HU) in ongoing clinical phase II studies in recurrent glioblastoma multiforme (GBM). CYP3A4 enzyme-inducing antiepileptic drugs (EIAEDs) like carbamazepine, phenytoin, and oxcarbazepine--as well as non-EIAEDs like valproic acid, levetiracetam, and lamotrigine--are frequently used in patients with GBM. Since CYP3A4 is the majo...

BACKGROUND This study evaluates the correlation between imatinib trough plasma concentrations (C(min)) and clinical response and safety in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in the Tyrosine Kinase Inhibitor OPtimization and Selectivity (TOPS) trial. DESIGN AND METHODS Patients were randomized 1:2 to 400 mg/day or 800 mg/day...

BACKGROUND Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy. METHODS In this open-label, multicenter trial with crossover design, we randomly assigned patients w...

Clinical studies using the tyrosine kinase inhibitor, imatinib mesylate (Gleevec®), in glioblastoma, have shown no major inhibition of tumor growth or extension of survival for patients, unlike those in chronic myeloid leukemia (CML) and gastrointestinal stromal tumors. The molecular mechanisms of action of imatinib in glioblastoma cells are still not well understood. In this study, we investig...

Abstract Oncogenic KIT or PDGFRA receptor tyrosine kinase mutations are compelling therapeutic targets in gastrointestinal stromal tumor (GIST), and treatment with the KIT/PDGFRA inhibitor imatinib is standard of care for patients advanced GIST. Polyclonal emergence secondary main mechanism progression, making it challenging to overcome KIT/PDGFRA-inhibitor resistance. It unclear whether there ...

Ouabain has shown powerful anti-proliferation activities in various cancers, but its effect on imatinibresistant chronic myeloid leukemia and toxicity normal mice not been investigated. Cell Counting Kit-8 assay was used to detect cytotoxicity reversal of ouabain with different concentration (0.01 μM, 0.1 1.0 10 μM) drug resistance imatinib-resistant cell line (K562/G01 line). Flow cytometry th...

Imatinib is a tyrosine kinase inhibitor that is effective in the treatment of chronic myeloid leukemia (CML). Not all patients achieve cytogenetic response. Some patients even lose the initial cytogenetic response. In this study, we investigated the active cellular transport of imatinib to gain a better understanding of the possible mechanisms of imatinib resistance. We used the leukemic cell l...